Next Generation

Immuno-Oncology Therapeutics

Apogenix develops innovative immuno-oncology therapeutics for the treatment of cancer and other malignant diseases. The company has built a promising pipeline of drug candidates that target different TNFSF-dependent signaling pathways, thereby restoring the anti-tumor immune response.

>> More about immuno-oncology


Asunercept (APG101)

Clinical Efficacy in Two Indications

Our lead immuno-oncology candidate asunercept (APG101) is in clinical development for the treatment of a variety of solid tumors and malignant hematological diseases. It has demonstrated statistically significant efficacy in a controlled phase II proof-of-concept trial in recurrent glioblastoma. Patients with a certain biomarker experienced the greatest benefit from treatment with asunercept. Apogenix is developing a companion diagnostic test based on this biomarker, so asunercept can be used as a personalized therapy.



The Apogenix team has created the HERA technology platform for the development of novel hexavalent receptor agonists that target different TNFSF-dependent signaling pathways, which play a crucial role in the regulation of the immune response. These fusion proteins offer clear advantages over other biologics such as antibodies and have the potential for broad application in oncology.



December 05, 2016
Apogenix Reports Final Phase I MDS Data at this Year´s American Society of Hematology (ASH) Meeting s

November 04, 2016
First Asian Clinical Trial with Asunercept (APG101) Initiated in Glioblastoma Patients